Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Heise

Showing results (91-100 of 150) with videos related to

Pageof 15
Sort By:
Diabetes, Obesity & Metabolism|December 21, 2022
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetesTim Heise, Jenny Chien, John M Beals, et al.
Molecular Genetics and Metabolism Reports|December 6, 2023
Pharmacodynamics, safety, tolerability and pharmacokinetics of a single oral dose of an engineered phenylalanine ammonia-lyase in patients with phenylketonuriaTimothy Nicholas Fazio, Louise Healy, Tim Heise, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|May 5, 2018
Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic StudyThomas Forst, Mohammed Khaled Alghdban, Annelie Fischer, et al.
Diabetes|February 11, 2016
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 DiabetesEle Ferrannini, Simona Baldi, Silvia Frascerra, et al.
Diabetes, Obesity & Metabolism|August 4, 2016
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitusHelle Linnebjerg, Eric Chen Quin Lam, Xin Zhang, et al.
Diabetologia|May 14, 2017
Bed rest and resistive vibration exercise unveil novel links between skeletal muscle mitochondrial function and insulin resistanceHelena C Kenny, Floriane Rudwill, Laura Breen, et al.
Diabetes, Obesity & Metabolism|December 24, 2016
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic studyThomas Forst, Alexander Falk, Grit Andersen, et al.
Diabetes, Obesity & Metabolism|June 21, 2018
Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetesGrit Andersen, Grégory Meiffren, Daniela Lamers, et al.
Diabetes Care|February 3, 2011
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trialTim Heise, Cees J Tack, Robert Cuddihy, et al.
Diabetes Technology & Therapeutics|May 1, 2004
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosolChristoph Kapitza, Tim Heise, Robert S Fishman, et al.
Pageof 15

Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
Diabetes, Obesity & Metabolism|December 21, 2022
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetesTim Heise, Jenny Chien, John M Beals, et al.
Molecular Genetics and Metabolism Reports|December 6, 2023
Pharmacodynamics, safety, tolerability and pharmacokinetics of a single oral dose of an engineered phenylalanine ammonia-lyase in patients with phenylketonuriaTimothy Nicholas Fazio, Louise Healy, Tim Heise, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|May 5, 2018
Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic StudyThomas Forst, Mohammed Khaled Alghdban, Annelie Fischer, et al.
Diabetes|February 11, 2016
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 DiabetesEle Ferrannini, Simona Baldi, Silvia Frascerra, et al.
Diabetes, Obesity & Metabolism|August 4, 2016
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitusHelle Linnebjerg, Eric Chen Quin Lam, Xin Zhang, et al.
Diabetologia|May 14, 2017
Bed rest and resistive vibration exercise unveil novel links between skeletal muscle mitochondrial function and insulin resistanceHelena C Kenny, Floriane Rudwill, Laura Breen, et al.
Diabetes, Obesity & Metabolism|December 24, 2016
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic studyThomas Forst, Alexander Falk, Grit Andersen, et al.
Diabetes, Obesity & Metabolism|June 21, 2018
Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetesGrit Andersen, Grégory Meiffren, Daniela Lamers, et al.
Diabetes Care|February 3, 2011
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trialTim Heise, Cees J Tack, Robert Cuddihy, et al.
Diabetes Technology & Therapeutics|May 1, 2004
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosolChristoph Kapitza, Tim Heise, Robert S Fishman, et al.
Pageof 15